JNJ and ABBV Related Headlines
Go Back- Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One
- Leerink highlights drug demand rebound after Memorial Day
- CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research
- HSBC lists 11 potential U.S. outperformers heading into earnings
- Trump to announce prescription drug price agreements
- Vida Ventures Marks Fourth Major Portfolio Acquisition in 2025, Capping a Record-Setting Year for Its Science-Led, Discipline-Driven Strategy
- Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
- FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
JNJ and ABBV Related Press Releases
Go Back- Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One
- CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research
- Vida Ventures Marks Fourth Major Portfolio Acquisition in 2025, Capping a Record-Setting Year for Its Science-Led, Discipline-Driven Strategy
